IDEXX LABORATORIES INC /DE (IDXX)
IDEXX LABORATORIES INC /DE (IDXX) from its SEC filings: 2025 revenue $4.3 billion (+10% vs the year before), net margin 25%, free cash flow $1.1 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Revenue (2025) | $4.3 billion |
| Revenue growth | +10% |
| Net income | $1.1 billion |
| Net margin | 24.6% |
| Free cash flow | $1.1 billion |
| Diluted EPS | $13.08 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +10% |
| Cash | $196.9 million |
| Long-term debt | $299.9 million |
| Share count, 1 year | -2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.